Allied Market Research published a report titled, "Optical Preclinical Imaging Market by Modality and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030." According to the report, the global optical preclinical imaging market was valued at $516.10 million in 2020 and is projected to reach $859.70 million by 2030, registering a CAGR of 5.2% from 2021 to 2030.
Market Overview
Optical preclinical imaging refers to the visualization of living animals for research purposes, including drug discovery and development. The technology enables researchers to monitor changes in animals in response to physiological or environmental stimuli - at the organ, tissue, cell, or molecular level. Noninvasive and in vivo imaging approaches have grown significantly in popularity for investigating animal models.
Optical preclinical imaging offers a virtual window into the animal, allowing real-time tracking of biological activities at the molecular level. It is simple to use, radiation-free, high-throughput, moderately priced, and delivers excellent sensitivity - making it highly effective for monitoring disease progression and evaluating drug candidate efficacy.
Key Growth Drivers
The following factors are driving growth in the global optical preclinical imaging market:
• Technological advancements in molecular imaging and nuclear medicine, including hybrid modalities such as CT, MRI, PET/CT, and SPECT/CT.
• Rising prevalence of chronic diseases and a growing aging population, fueling demand for advanced drug discovery tools.
• Increased funding for preclinical research by both private and public organizations globally.
• Rising demand for noninvasive small animal imaging techniques for preclinical in vivo studies.
• Surge in research & development of new drug molecules and therapies for emerging diseases.
• COVID-19-related preclinical research and clinical trials accelerating adoption of imaging solutions.
Market Restraints
High costs associated with optical preclinical imaging systems, along with the need for regular and costly maintenance of imaging devices, remain key constraints on global market growth. Disruptions caused by the COVID-19 pandemic also led to delays in non-essential procedures at hospitals and research centers worldwide.
Market Segmentation Highlights
By Modality:
• Bioluminescence & Fluorescence Imaging Systems (dominant segment in 2020)
• Standalone Fluorescence Imaging Systems
• Optical + X-ray & Optical + CT
By End User:
• Pharma & Biotech Companies
• Academic & Government Research Institutes
• Contract Research Organizations (highest growth segment in 2020)
Regional Insights
North America accounted for the largest market share in 2020, driven by robust R&D infrastructure, rapid adoption of novel molecular imaging technologies, and the presence of leading market players. The U.S. remains the dominant country in the region owing to significant investments in drug discovery.
Asia-Pacific is projected to witness the fastest growth, registering a CAGR of 8.4% during the forecast period, driven by strong government support for pharmaceutical and biotechnology R&D, increasing public-private investments, and expanding translational research initiatives in healthcare.
Key Players Profiled
The report profiles the following leading companies operating in the global optical preclinical imaging market:
• Berthold Technologies GmbH & Co. KG
• Endress+Hauser (Analytik Jena US LLC)
• Fujifilm Corporation (Fujifilm VisualSonics Inc.)
• LI-COR Biosciences, Inc.
• Miltenyi Biotec B.V. & CO. KG
• PerkinElmer, Inc.
• Rigaku Corporation (MILabs B.V.)
• TriFoil Imaging
• Vieworks Co., Ltd.
• Vilber Smart Imaging Ltd.
Analyst Perspective
According to Allied Market Research analysts, the rise in biomedical research to prevent and treat diseases, combined with the growing adoption of minimally invasive advanced imaging technologies, is expected to significantly boost market growth. The use of preclinical in vivo imaging for translational medicine helps de-risk drug candidates, shorten time to clinic, and lower costs while maximizing biological understanding. Moreover, untapped emerging markets - characterized by improved healthcare infrastructure, unmet healthcare needs, and increasing R&D activities - present significant opportunities for key market players.
0 Comments